STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 401–500 of 1,004
Błach, J., Wojas‐Krawczyk, K., Nicoś, M., & Krawczyk, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169030 · Cited by 56
“Likewise, NSCLC patients with overlapping of KRAS and STK11/LKB1 mutations’ have showed a higher clinical sensitivity for ICIs due to epigenetic inhibition of stimulator of INF genes (STING) [24,29,42].”
BackgroundZulato, E., Attili, I., Pavan, A., Nardo, G., Bianco, P. D., Bragadin, A. B., Verza, M., Pasqualini, L., Pasello, G., Fassan, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0833-7 · Cited by 49
Thummalapalli, R., Bernstein, E., Herzberg, B. O., Li, B. T., Iqbal, A. N., Preeshagul, I. R., Santini, F. C., Eng, J., Ladanyi, M., Yang, S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00030 · Cited by 61
“…TRAEs (no previous platinum exposure: fi ve of 28 patients with G3 1 TRAEs [18%], previous platinum exposure: 11 of 77 patients with G3 1 TRAEs [14%]; OR, 0.77; P 5 .760), or We then sought to identify the aspects of previous anti – PD-(L) 1 therapy exposure that predispose patients to…”
BackgroundInfluentialFacts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3655 · Cited by 46
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 55
“124,125 In fact, STK11 - mutated NSCLC displays decreased PD-L1 expression and poor response to anti-PD-1 therapy, though this response was reversed with the administration of IL-6 blockade.”
BackgroundAlban, T. J., Riaz, N., Parthasarathy, P. B., Makarov, V., Kendall, S. M., Yoo, S., Shah, R., Weinhold, N., Srivastava, R. M., Ma, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03240-y · Cited by 53
“Initially, we confirmed the known association of STK11 and KEAP1 with nonresponders, as previously reported 26 (Extended Data Fig.”
Self-citationHermans, B. C. M., Derks, J. L., Thunnissen, E., van Suylen, R. J., den Bakker, M. A., Groen, H. J. M., Smit, E. F., Damhuis, R. A. M., van den Broek, E. C., Stallinga, C. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.022 · Cited by 50
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Pathak, R., Pharaon, R. R., Mohanty, A. R., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020) · Cancers · doi:10.3390/cancers12123851 · Cited by 51
“Recent research has demonstrated that some genomic alterations might confer primary resistance to ICIs, including STK11 and KEAP1 mutations [4,5].”
BackgroundOn target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 44
Yang, S., Huang, Y., & Zhao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878740 · Cited by 54
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
East, P., Kelly, G. P., Biswas, D., Marani, M., Hancock, D. C., Creasy, T. H., Sachsenmeier, K. F., Swanton, C., Downward, J., & Trécesson, S. D. C. (2022) · Nature Communications · doi:10.1038/s41467-022-33290-0 · Cited by 43
Targeting KRAS G12C with Covalent Inhibitors
Ostrem, J. M. L., & Shokat, K. M. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041621-012549 · Cited by 52
Overcoming KRAS-Mutant Lung Cancer
Luo, J., Ostrem, J. M. L., Pellini, B., Imbody, D., Stern, Y. E., Solanki, H. S., Haura, E. B., & Villaruz, L. C. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_360354 · Cited by 59
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Contribution of Internet of Things (IoT) in improving agricultural systems
Duguma, A. L., & Bai, X. (2023) · International Journal of Environmental Science and Technology · doi:10.1007/s13762-023-05162-7 · Cited by 50
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 58
Self-citationStratmann, J., Althoff, F. C., Doebel, P., Rauh, J., Trummer, A., Hünerlitürkoglu, A. N., Frost, N., Yildirim, H., Christopoulos, P., Burkhard, O., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113911 · Cited by 50
Mei, T., Wang, T., & Zhou, Q. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01324-0 · Cited by 60
“These KRAS-STK11/LKB1 co-mutant tumors tended to show greater resistance to PD-1 inhibitors [47], while the patients with the KRAS-TP53 co-mutation were more sensitive to PD-1 inhibitors [48].”
BackgroundKlein, O., Senko, C., Carlino, M. S., Markman, B., Jackett, L. A., Gao, B., Lum, C., Kee, D., Behren, A., Palmer, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908771 · Cited by 51
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
Rosellini, P., Amintas, S., Caumont, C., Veillon, R., Galland-Girodet, S., Cuguillière, A., Nguyen, L., Domblides, C., Gouverneur, A., Merlio, J.-P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.026 · Cited by 44
Genomic landscape of lung adenocarcinomas in different races
Shi, H., Seegobin, K., Heng, F., Zhou, K., Chen, R., Qin, H., Manochakian, R., Zhao, Y., & Lou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.946625 · Cited by 48
“Frontiers in Oncology 09 KRAS mutant lung adenocarcinomas (51, 52).”
BackgroundTumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer
Lu, H., Lou, H., Wengert, G., Paudel, R., Patel, N. R., Desai, S., Crum, B., Linton‐Reid, K., Chen, M., Li, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101092 · Cited by 50
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 58
Shen, R., Martin, A., Ni, A., Hellmann, M., Arbour, K. C., Jordan, E., Arora, A., Ptashkin, R., Zehir, A., Kris, M. G., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00307 · Cited by 42
Self-citationKRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
Passiglia, F., Malapelle, U., Re, M. D., Righi, L., Pagni, F., Furlan, D., Danesi, R., Troncone, G., & Novello, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.023 · Cited by 47
Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma
Huang, R. S. P., Haberberger, J., Murugesan, K., Danziger, N. A., Hiemenz, M., Severson, E. A., Duncan, D. L., Ramkissoon, S. H., Ross, J. S., Elvin, J. A., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00780-3 · Cited by 46
Self-citationSpotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang, S. S., & Nagasaka, M. (2021) · Lung Cancer: Targets and Therapy · doi:10.2147/lctt.s334623 · Cited by 41
Ricciuti, B., Son, J., Okoro, J. J., Mira, A., Patrucco, E., Eum, Y., Wang, X., Paranal, R., Wang, H., Lin, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2719 · Cited by 42
Self-citationGenomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Scharpf, R. B., Balan, A., Ricciuti, B., Fiksel, J., Cherry, C., Wang, C., Lenoue-Newton, M. L., Rizvi, H. A., White, J. R., Baras, A. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1731 · Cited by 49
“…also been linked with inferior outcomes in NSCLC (61, 62) and in PD-L1 – positive NSCLC, STK11, and KRAS comutations have been shown to confer resistance to anti – PD-1/PD-L1 therapy with signi fi cantly lower objective response rates, shorter progression-free survival and overall survival (62).”
Self-citationTang, S., Xue, Y., Qin, Z., Fang, Z., Sun, Y., Yuan, C., Pan, Y., Zhao, Y., Tong, X., Zhang, J., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad028 · Cited by 43
Self-citationAssociation between abnormal lipid metabolism and tumor
Li, C., Wang, F., Cui, L., Li, S., Zhao, J., & Liao, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134154 · Cited by 56
“In pancreatic cancer, HSL expression is down regulated, destruction of KRAS-HSL axis reduces lipid storage, reprogrammed tumor cell metabolism, and inhibits invasive migration of pancreatic cancer (47).”
BackgroundInfluentialNivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Pouyiourou, M., Kraft, B. N., Wohlfromm, T., Ståhl, M., Kubuschok, B., Löffler, H., Hacker, U. T., Hübner, G., Weiss, L., Bitzer, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42400-5 · Cited by 45
“3, 9p24, STK11 and KEAP1 areassociated with animmunologically ‘ cold ’ tumor microenvironment and immunotherapy resistance 37 – 44 .”
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 51
Caiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 43
Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 44
STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
Granado‐Martínez, P., García-Ortega, S., González‐Sánchez, E., McGrail, K., Selgas, R., Grueso, J., Gil, R., Naldaiz‐Gastesi, N., Rhodes, A. C., Hernández‐Losa, J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1092-0 · Cited by 44
Noordhof, A. L., Damhuis, R. A. M., Hendriks, L. E. L., Langen, A. J. D., Timens, W., Venmans, B. J. W., & van Geffen, W. H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.001 · Cited by 46
Moutafi, M. K., Martínez-Morilla, S., Divakar, P., Vathiotis, I. A., Gavrielatou, N., Aung, T. N., Yaghoobi, V., Fernandez, A. I., Zugazagoitia, J., Herbst, R. S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.04.009 · Cited by 50
Sen, U., Coleman, C. J., Gandhi, N. S., Jethalia, V., Demircioğlu, D., Elliott, A., Vanderwalde, A. M., Hayatt, O., de Stanchina, E., Halmos, B., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2745 · Cited by 58
Vernieri, C., Signorelli, D., Galli, G., Ganzinelli, M., Moro, M., Fabbri, A., Tamborini, E., Marabese, M., Caiola, E., Broggini, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.011 · Cited by 43
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna, L., Guibert, N. M., Milia, J., & Mazières, J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0652-3 · Cited by 44
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41
Notch Transduction in Non-Small Cell Lung Cancer
Sharif, A., Shaji, A., Chammaa, M., Pawlik, E., & Fernandez‐Valdivia, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165691 · Cited by 46
Down-regulation of A20 promotes immune escape of lung adenocarcinomas
Breitenecker, K., Homolya, M., Luca, A. C., Lang, V., Trenk, C., Petroczi, G., Mohrherr, J., Horvath, J., Moritsch, S., Haas, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc3911 · Cited by 47
Tanaka, I., Furukawa, T., & Morise, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02165-7 · Cited by 47
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
Zhang, F., Wang, J., Xu, Y., Cai, S., Li, T., Wang, G., Li, C., Zhao, L., & Hu, Y. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00243-7 · Cited by 43
Self-citationTamiya, Y., Matsumoto, S., Zenke, Y., Yoh, K., Ikeda, T., Shibata, Y., Kato, T., Nishino, K., Nakamura, A., Furuya, N., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.12.019 · Cited by 46
Gao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
Rączkowska, A., Paśnik, I., Kukiełka, M., Nicoś, M., Budzinska, M. A., Kucharczyk, T., Szumiło, J., Krawczyk, P. A., Crosetto, N., & Szczurek, E. (2022) · BMC Cancer · doi:10.1186/s12885-022-10081-w · Cited by 53
“Likewise, loss of STK11/LKB1 overlapping with oncogenic KRAS mutations is associated with increased neutrophil recruitment, and decreased T-cells infiltration in lung cancer tumors [70].”
BackgroundBeyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases
Seok, J. K., Kim, M., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01452-3 · Cited by 45
Self-citationDynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer
Zhang, F., Bai, H., Gao, R., Fei, K., Duan, J., Zhang, Z., Wang, J., & Hu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02642-4 · Cited by 44
Self-citationThe Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
Mograbi, B., Heeke, S., & Hofman, P. M. (2021) · Diagnostics · doi:10.3390/diagnostics11020196 · Cited by 46
“In contrast, other studies reported that lung cancer patients with STK11 mutated tumors could respond to ICIs [114–116].”
InfluentialBiomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 44
“[69] demonstrated KRAS and STK11/LKB1 co-mutation was relevant to PD-L1 negativity in intermediate or high TMB lung adenocarcinoma (LUAC).”
BackgroundFederico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 46
Scalera, S., Ricciuti, B., Mazzotta, M., Calonaci, N., Alessi, J. V., Cipriani, L., Bon, G., Messina, B., Lamberti, G., Federico, A. D., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.002 · Cited by 42
Self-citationKRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
Rosell, R., Codony‐Servat, J., González, J., Santarpía, M., Jain, A. S., Shivamallu, C., Wang, Y., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Nilsson, J. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104228 · Cited by 47
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Ngoi, N. Y. L., Tang, T., Gaspar, C. F., Pavlick, D. C., Buchold, G. M., Scholefield, E. L., Parimi, V., Huang, R. S. P., Janovitz, T., Danziger, N. A., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae011 · Cited by 49
“44,45 Mutational signatures are thought to infer a tumor’s mutational fingerprints and elaborate on multiple cancer processes involved in tumor initiation and progression.”
BackgroundSelf-citationPrecision Immunotherapy for STK11/KEAP1-Mutant NSCLC
Ricciuti, B., & Garassino, M. C. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.03.002 · Cited by 47
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma
Weaver, C., Satter, K. B., Richardson, K. P., Tran, L. K. H., Tran, P. M. H., & Purohit, S. B. (2022) · Biomedicines · doi:10.3390/biomedicines10112953 · Cited by 55
de Lima, V. C. C., Corassa, M. P., Saldanha, E. F., Freitas, H., Arrieta, O. G., Raez, L. E., Samtani, S., Ramos-Ramírez, M., Rojas, C., Burotto, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.010 · Cited by 47
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Long, L.-L., Ma, S.-C., Guo, Z.-Q., Zhang, Y.-P., Fan, Z., Liu, L.-J., Liu, L., Han, D.-D., Leng, M.-X., Wang, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1740 · Cited by 45
Self-citationHe, K., Berz, D., Gadgeel, S. M., Iams, W. T., Bruno, D. S., Blakely, C. M., Spira, A. I., Patel, M. R., Waterhouse, D. M., Richards, D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.016 · Cited by 41
“Checkpoint inhibitor (CPI) therapy has changed the treatment landscape for NSCLC. 11 Despite these advances, not all patients respond to CPI (primary resistance), and most who benefit initially develop resistance and experience disease progression (acquired resistance).”
BackgroundInfluentialPrognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 42
“STK11/LKB1 mutations are detected in 10–20% of NSCLC [93] and could result in a “cold” tumor with poor responses to ICIs [94,95].”
BackgroundThummalapalli, R., Ricciuti, B., Bandlamudi, C., Muldoon, D. M., Rizvi, H. A., Elkrief, A., Luo, J., Alessi, J. V., Pecci, F., Lamberti, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1207 · Cited by 40
Self-citationGenomic medicine and personalized treatment: a narrative review
Khan, A. H., Barapatre, A. R., Babar, N., Doshi, J. D., Ghaly, M., Patel, K. G., Nawaz, S., Hasana, U., Khatri, S. P., Pathange, S., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002965 · Cited by 50
“These findings suggest that STK11/LKB1 mutations can be employed as a predictive biomarker for PD-1 inhibitor efficacy potentially informing customized treatment options for KRAS-mutant patients [ 89 ] .”
Inoue, Y., Yoshimura, K., Nishimoto, K., Inui, N., Karayama, M., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11818 · Cited by 39
Discovering functional evolutionary dependencies in human cancers
Mina, M., Iyer, A., Tavernari, D., Raynaud, F., & Ciriello, G. (2020) · Nature Genetics · doi:10.1038/s41588-020-0703-5 · Cited by 41
Guaitoli, G., Tiseo, M., Maïo, M. D., Friboulet, L., & Facchinetti, F. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-941 · Cited by 40
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
Zhou, F., Huang, Y., Cai, W., Li, J., Su, C., Ren, S., Wu, C., & Zhou, C. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.006 · Cited by 38
Lu, S., Shi, J., Zhang, X., Kong, F., Liu, L., Dong, X., Wang, K., & Shen, D. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03080-y · Cited by 45
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0432 · Cited by 40
Self-citationEfficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Vokes, N. I., Pan, K., & Le, X. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231161409 · Cited by 45
Yang, S., Gedvilaite, E., Ptashkin, R. N., Chang, J. C., Ziegler, J., Mata, D. A., Villafania, L. B., Nafa, K., Hechtman, J. F., Benayed, R., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.004 · Cited by 47
Self-citationThe Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 57
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Robles-Oteíza, C., Hastings, K., Choi, J., Sirois, I., Ravi, A., Expósito, F., de Miguel, F. J., Knight, J., López‐Giráldez, F., Choi, H., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231106 · Cited by 46
“MFI, mean fluorescence intensity. compared to those with TP53 -WT tumors (Skoulidis et al., 2018), further suggesting that p53 deficiency is not the only mediator of primary ICI resistance in the Msh2 KO 368T1 tumors.”
Self-citationRicciuti, B., Fusco, F., Cooper, A. J., Garbo, E., Pecci, F., Aldea, M. D., Wang, X., Mayoral, M., Ginsberg, M. S., Sholl, L. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1115 · Cited by 53
Self-citationRen, Y., Chen, J., Chen, P., Hao, Q., Cheong, L.-K., Tang, M., Hong, L., Hu, X., Yap, C. T., Bay, B., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.018 · Cited by 43
Michelotti, A., de Scordilli, M., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126748 · Cited by 42
Cinausero, M., Laprovitera, N., Maglio, G. D., Gerratana, L., Riefolo, M., Macerelli, M., Fiorentino, M., Porcellini, E., Buoro, V., Gelsomino, F., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919885540 · Cited by 40
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Yang, Y., Yu, Y., & Lü, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1622-5 · Cited by 40
“that STK11/LKB1 alterations might act as a driver of primary resistance to PD-1 inhibitors in KRAS-mutant LUAC patients (Skoulidis et al., 2018).”
BackgroundChoi, J., Lee, H. J., Yoon, S., Ryu, H.-M., Lee, E., Jo, Y., Seo, S., Kim, D., Lee, C. H., Kim, W., et al. (2020) · PubMed · Cited by 45
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 39
“For example, LBK1 mutant lung cancers have poor immune involvement and respond poorly to immunotherapy (59).”
BackgroundLindsay, C. R., Shaw, E. C., Moore, D. A., Rassl, D. M., Jamal‐Hanjani, M., Steele, N. L., Naheed, S., Dick, C., Taylor, F., Adderley, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01407-9 · Cited by 40
The Role of Circular RNAs in the Drug Resistance of Cancers
Liu, X., Zhang, Q., Guo, J., Zhang, P., Liu, H., Tian, Z., Zhang, C., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.790589 · Cited by 40
“Moreover, a novel protein encoded by circASK1 activates ASK1-dependent apoptosis, thereby ameliorating gefitinib resistance in LUAD (81).”
BackgroundTargeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症:英文版 · doi:10.1002/cac2.12377 · Cited by 39
“Therefore, it is imperative to identify the populations thatmay benefit from ICIs.”
BackgroundInfluentialSelf-citationGu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
“Moreover, clinical data support that LUAC patients with this pattern of tumor immunity can largely benefit from anti-PD-1 monotherapy [17].”
BackgroundSingh, D., & Siddique, H. R. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10141-y · Cited by 41
Duan, J., Zhang, Y., Chen, R., Liang, L., Huo, Y., Lü, S., Zhao, J., Hu, C., Sun, Y., Yang, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101302 · Cited by 48
Self-citationEZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas
DuCote, T. J., Song, X., Naughton, K. J., Chen, F., Plaugher, D. R., Childress, A. R., Edgin, A. R., Skaggs, E. M., Qu, X., Liu, J., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0399 · Cited by 38
“Consistent with LKB mutation predicting poor responsetoimmunotherapy(34–36),anti-PD1treatmentalonehadonlyasmall impact on tumor growth (Fig.”
Self-citationCui, J., Lian, Z., Zhang, Y., & Xue, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-81971-5 · Cited by 39
Immune landscape and immunotherapy for penile cancer
Tang, Y., Hu, X., Wu, K., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055235 · Cited by 40
“In addition, the rarity of STK11 mutation and MDM2 proliferation in PSCC (62), which was found to play an important role in resistance to ICI in lung adenocarcinoma (63) and tumor hyperprogression after ICI therapy (64), respectively, also supports the potential application of ICI in penile cancer.”
ResultChoudhury, N. J., Lavery, J. A., Brown, S., de Bruijn, I., Jee, J., Tran, T. N., Rizvi, H. A., Arbour, K. C., Whiting, K. A., Shen, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0580 · Cited by 43
Self-citationQiao, M., Zhou, F., Liu, X., Jiang, T., Wang, H., Li, X., Zhao, C., Cheng, L., Chen, X., Ren, S., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00471-6 · Cited by 38
“…-mutant lung adenocarcinoma into three subgroups on account of concomitant co-mutations, namely STK11/LKB1 mutations (KL subgroup), TP53 mutations (KP subgroup), and (KRAS-only sub-group) and revealed that KL subgroup responded poorly to ICIs, with an objective response rate (ORR) of only 7.4% [4].”
BackgroundResultInfluentialWang, H.-Y., Guo, J., Shang, X., & Wang, Z.-H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106574 · Cited by 32
Shen, X., Zhao, Y., Liu, G., Zhou, H.-L., Fan, J., Zhang, L., Li, Y., Wang, Y., Liang, J., & Xu, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117923 · Cited by 34
Giustini, N., & Bazhenova, L. A. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s235102 · Cited by 38
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Self-citationPezzuto, F., Hofman, V., Bontoux, C., Fortarezza, F., Lunardi, F., Calabrese, F., & Hofman, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107249 · Cited by 37
Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications
Tierno, D., Grassi, G., Scomersi, S., Bortul, M., Generali, D., Zanconati, F., & Scaggiante, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119688 · Cited by 37
“The latter has already been associated with resistance to ICPIs, as it attenuates the immune response [79,80], but few studies have considered it in breast cancer.”
Background
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.